KRAS and lung adenocarcinoma: PIK3CA mutations can co-occur with activating mutations in RTKs such as EGFR, KRAS, and ALK in lung adenocarcinomas [126], as well as with the loss of PTEN in endometrial and breast cancer [127,128,129].